Annexon (ANNX) Net Income towards Common Stockholders (2019 - 2026)

Annexon's (ANNX) quarterly Net Income towards Common Stockholders came in at -$78.1 million in Q1 2026, down 9.25% year-on-year from -$86.0 million in Q1 2025, and down 61.78% quarter-over-quarter from -$48.3 million in Q4 2025.

Annexon (ANNX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Annexon's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$78.1 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 9.25% year-over-year to -$78.1 million in Q1 2026; TTM through Mar 2026 was -$232.3 million, a 25.9% decrease from a year earlier, with the FY2025 full-year figure at -$208.5 million, down 50.9% from the prior year.
  • Net Income towards Common Stockholders eased to -$78.1 million in Q1 2026 per ANNX's latest filing, from -$48.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$29.6 million in Q2 2024 and bottomed at -$160.9 million in Q4 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$51.0 million (2025), against an average of -$59.2 million.
  • Across the five-year window, Net Income towards Common Stockholders slumped 367.93% in 2023 and jumped 69.8% in 2024, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$34.4 million in 2022, then slumped by 367.93% to -$160.9 million in 2023, then soared by 69.8% to -$48.6 million in 2024, then rose by 0.69% to -$48.3 million in 2025, then plunged by 61.78% to -$78.1 million in 2026.
  • Per Business Quant, the three latest ANNX Net Income towards Common Stockholders figures stand at -$78.1 million (Q1 2026), -$48.3 million (Q4 2025), and -$54.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 Annexon 1.02 Bn 1.02 Bn - -78.07 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -78.07 Mn
Dec 31, 2025 -48.26 Mn
Sep 30, 2025 -54.92 Mn
Jun 30, 2025 -51.01 Mn
Mar 31, 2025 -71.46 Mn
Dec 31, 2024 -48.59 Mn
Sep 30, 2024 -34.82 Mn
Jun 30, 2024 -29.61 Mn
Mar 31, 2024 -70.62 Mn
Dec 31, 2023 -160.89 Mn
Sep 30, 2023 -78.77 Mn
Jun 30, 2023 -82.85 Mn
Mar 31, 2023 -54.96 Mn
Dec 31, 2022 -34.38 Mn
Sep 30, 2022 -35.05 Mn
Jun 30, 2022 -37.14 Mn
Mar 31, 2022 -35.37 Mn
Dec 31, 2021 -37.37 Mn
Sep 30, 2021 -35.60 Mn
Jun 30, 2021 -31.29 Mn